MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2024 International Congress

    Personality may influence the response to apomorphine infusion in Parkinson’s disease patients

    M. Boussac, E. Harroch, C. Barthelemy, F. Ory-Magne, C. Leung, M. Fabbri, C. Arbus, C. Brefel-Courbon (Toulouse, France)

    Objective: to evaluate the impact of personality on quality-of-life (QoL) amelioration after treatment by Continuous Subcutaneous Apomorphine Infusion (CSAI) in Parkinson’s disease (PD). Background: PD…
  • 2024 International Congress

    Comparing digital gait and turning measures from a prescribed gait test in the clinic/laboratory versus the same test at home in people with Parkinson’s disease

    V. Shah, C. Silva-Batista, P. Burgos, A. Ragothaman, P. Carlson-Kuhta, K. Sowalsky, F. Horak, M. Mancini (Portland, USA)

    Objective: We aim to compare the performance of the same prescribed walk test in the laboratory/clinic versus in the home. Background: With the advent of…
  • 2024 International Congress

    Centralizing brain tissue donation for a large multi-site Parkinson’s disease (PD) study

    L. Heathers, T. Foroud, G. Antonopoulos, K. Mantravadi, B. Lenfert (Indianapolis, USA)

    Objective: Brain tissue analysis is an invaluable resource to better understand PD progression, but there is limited access to this resource and swift postmortem collection…
  • 2024 International Congress

    Treatment Patterns With Long-Term Foslevodopa/Foscarbidopa Use in Parkinson’s Disease

    J. Aldred, T. Henriksen, M. Bouchard, J. Martínez-Castrillo, M. Soileau, D. Standaert, L. Bergmann, R. Gupta, P. Kukreja, M. Shah, S. Isaacson (Spokane, USA)

    Objective: To assess long-term treatment switch patterns and discontinuation rates in patients (pts) with Parkinson’s disease (PD) treated with foslevodopa/foscarbidopa (LDp/CDp) mono- or combination therapy.…
  • 2024 International Congress

    A Post Hoc Efficacy Analysis of Phase 3 Trials of Continuous Subcutaneous Foslevodopa/Foscarbidopa in Patients With Parkinson’s Disease

    M. Soileau, M. Bouchard, I. Malaty, J. Parra, L. Bergmann, R. Gupta, A. Spiegel, E. Freire-Alvarez (Georgetown, USA)

    Objective: To further evaluate the efficacy of foslevodopa/foscarbidopa (LDp/CDp), a soluble formulation of levodopa/carbidopa (LD/CD) prodrugs delivered by 24 hour/day customizable continuous subcutaneous infusion, for…
  • 2024 International Congress

    Integrated Clinical Research Intern Program: Impact Upon Recruitment of Participants for Therapeutic Studies Aimed at Parkinson’s Disease (PD) Prevention.

    L. Lemon, A. Faraday, J. Nevins, M. Nygard, M. Mcmahon (Cincinnati, USA)

    Objective: To discuss the development and benefit of an online internship program created to expand recruitment and retention within a PD cohort and introduce students…
  • 2024 International Congress

    Assessment of Motor and Non-Motor Alterations Impacting Functionality in Parkinson’s Disease Patients

    R. Dias, M. Piemonte, G. Gomes, L. Bitaraes (Sao Paulo, Brazil)

    Objective: To investigate the impact of motor and non-motor changes on the functionality of individuals with Parkinson's disease Background: Parkinson's disease (PD) is the second…
  • 2024 International Congress

    Dose-dependent alterations of lysosomal activity and alpha-synuclein level in peripheral blood monocyte-derived macrophages and SH-SY5Y neuroblastoma cell line by upon inhibition of mTOR kinase activity

    A. Bezrukova, K. Basharova, G. Baydakova, E. Zakharova, S. Pchelina, T. Usenko (Gatchina, Russian Federation)

    Objective: To evaluate the perceptivity of mTOR kinase activity inhibition for Parkinson's disease therapy (PD). Background: The protein kinase mTOR is currently considered as a…
  • 2024 International Congress

    Comparative-effectiveness of Foscarbidopa/foslevodopa (LDp/CDp) versus Oral Therapies in Advanced Parkinson’s Disease: A Propensity Matched Study

    D. Standaert, A. Fasano, F. Ory-Magne, D. Kern, O. de Fabregues, T. Oeda, D. Safarpour, Z. Baldwin, C. Yan, S. Wang, K. Onuk, P. Kukreja, L. Bergmann, V. Fung (Birmingham, USA)

    Objective: To assess long-term effectiveness outcomes in people with advanced Parkinson’s Disease (aPD) on LDp/CDp versus those on oral PD therapies (standard of care, SoC).…
  • 2024 International Congress

    Opicapone real-world experience in early motor fluctuations: 3-months analysis of the REONPARK study.

    L. Lopez Manzanares, J. Garcia Caldentey, R. Garcia-Ramos, M. Cerdan Sanchez, B. Solano Vila, G. Castilla-Fernandez, I. Pijuan Jimenez, I. Tegel Ayuela (Madrid, Spain)

    Objective: The REONPARK study aims to evaluate COMT inhibitor (iCOMT) effectiveness and tolerability in alleviating motor complications associated with L-dopa treatment in Parkinson’s Disease patients…
  • « Previous Page
  • 1
  • …
  • 42
  • 43
  • 44
  • 45
  • 46
  • …
  • 338
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • “Striatal Hand Signs” and early diagnosis of Parkinson's Disease: The “Monkey-Wrench Sign”.
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • An atypical and interesting feature of Parkinson´s disease
  • Yerba Mate (Ilex paraguaiensis) protects dopaminergic neurons degeneration and improve their maturation in culture
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley